Emerging retatrutide, a combined-action treatment targeting simultaneously GLP-1 and GIP receptors, is creating considerable buzz within the healthcare community. Preliminary clinical research have revealed impressive decreases in overall mass and improvements in metabolic markers for patients wi… Read More